Novavax Stock- Novavax shakes up leadership with two promotions and departure of CFO; Moderna, Novavax shots added to mix-and-match study in the UK – Endpoints News
Novavax has had a busy month, filled with supply chain issues and manufacturing deals that have affected the rollout of its Covid-19 vaccine. Tuesday, the company announced updates to its leadership team.
CFO Greg Covino will step down from that role after just five months for personal reasons, the release said, but take on a new role as executive advisor. John Trizzino, current chief commercial officer and chief business officer, will take the CFO role over in the interim.
The Maryland company also announced the promotion of Gale Smith and the appointment of Troy Morgan. Smith takes over the roles of chief scientist and SVP of discovery and preclinical research, while Morgan becomes chief compliance officer in a newly created position.
Smith has been with Novavax since 2004, and holds patents for the baculovirus-insect cell expression system as well as seasonal influenza vaccines and adjuvants. He’s overseen discovery and pre-clinical research since his start with the company, and played a significant role in the discovery of Novavax’s Covid-19 vaccine. President of R&D Gregory Glenn said in a statement:
Dr. Smith’s scientific insights and leadership are an invaluable asset to Novavax and have already delivered vaccines that protect the health of millions worldwide. This well-deserved promotion reflects not only his major contributions in creating our COVID-19 vaccine candidate, but well over a decade of dedication to improving our technology platform.
Morgan comes to Novavax from EMD Serono, where he held the same role of CCO. Before that, he held roles in senior leadership at Merck KGaA, Sanofi and Biogen.
“We welcome Troy’s specialized expertise in global compliance regulations and requirements as we look toward commercialization and work to efficiently deliver our vaccine around the world in the fight against the COVID-19 pandemic,” CEO Stanley Erck said.
Recent supply shortages have led to a delay in Novavax’s timeline for full-speed Covid-19 vaccine production, according to Reuters. The company has the goal of hitting a production target of 150 million doses a month, but supply shortages that include bags used to grow cells have delayed that.
That news came about a week after the company announced that it would allow its placebo group to receive its Covid-19 vaccine. In March, a UK trial showed a final efficacy of 96% against mild, moderate and severe Covid-19 cases in the UK, but the vaccine faltered against the South African variant, where it registered 50% efficacy.
Novavax has pledged 60 million doses of its shot to the UK as part of a deal signed in August.
Moderna, Novavax shots added to mix-and-match study in the UK
Shots from Moderna and Novavax have been added to a study that looks to mix and match two different Covid-19 vaccines, Reuters reports.
The study in the UK is known as COM-COV and was launched in February to see if mixing up shots from different drugmakers elicits an adequate immune response, with the purpose of using the existing vaccines more flexibly.
The study already includes the Pfizer and AstraZeneca vaccines with volunteers receiving a dose of either of those drugs before being randomized to take a second shot of the same vaccine or one of Moderna or Novavax. The study has enrolled 1,050 patients, Reuters said.
Results from the trial are expected as soon as April or May.
Reports of rare blood clots have led to skepticism in some European governments, including France and Germany. Those countries have limited what age groups are permitted to receive that jab.
For a look at all Endpoints News coronavirus stories, check out our special news channel.
Novavax Stock – Novavax shakes up leadership with two promotions and departure of CFO; Moderna, Novavax shots added to mix-and-match study in the UK – Endpoints News
Tags: Novavax Stock
Latest News on C N N.